Stockholders’ Equity - Schedule of Activity for the Company’s IPO Warrants (Details) - Warrant [Member] - USD ($) |
3 Months Ended | |
|---|---|---|
Dec. 31, 2025 |
Mar. 31, 2026 |
|
| Schedule of Activity for the Company’s IPO Warrants [Line Items] | ||
| Number of Shares Underlying Outstanding Warrants, Warrants granted | ||
| Weighted- Average Exercise Price, Warrants granted | ||
| Weighted- Average Remaining Contractual Term (in Years), Warrants granted | ||
| Aggregate Intrinsic Value, Warrants granted | ||
| Number of Shares Underlying Outstanding Warrants, Outstanding at Ending | 478,419 | 478,419 |
| Weighted- Average Exercise Price, Outstanding at Ending | $ 60 | $ 60 |
| Weighted- Average Remaining Contractual Term (in Years), Outstanding at Ending | 6 months 14 days | 3 months 14 days |
| Aggregate Intrinsic Value, Outstanding at Ending |
| X | ||||||||||
- Definition Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
- Definition Intrinsic value of outstanding award under warrants granted. Excludes share and unit options. No definition available.
|
| X | ||||||||||
- Definition The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Weighted-average contractual term remaining for equity-based award excluding option, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|